I would argue that MPL would eat their lunch regardless.
If MPL continues to show years of extended life with low to noe side effects then Relyvrio would stuggle to maintain much market presence at all.
There could be a cohort that Relyvrio is a better solution but the way things are heading it is of low likelihood IMO.
Then Relyvio is only for MND, where MPL is good for some cancers, very likely to succeed with other neurological diseases...
adreamer
I would argue that MPL would eat their lunch regardless. If MPL...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.5¢ |
Change
0.005(2.78%) |
Mkt cap ! $71.26M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.5¢ | 18.0¢ | $77.38K | 429.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 127000 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 257846 | 7 |
View Market Depth
| Last trade - 13.08pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
18.0¢ |
Change
0.005 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 18.0¢ | 18.0¢ | 18.0¢ | 106443 | ||
| Last updated 12.33pm 30/05/2024 ? | |||||
| PAA (ASX) Chart |